3,846 Shares in Tempus AI, Inc. (NASDAQ:TEM) Acquired by Stifel Financial Corp

Stifel Financial Corp purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,846 shares of the company’s stock, valued at approximately $218,000.

A number of other large investors have also modified their holdings of the company. Alphabet Inc. purchased a new stake in shares of Tempus AI during the second quarter worth $54,289,000. Pier Capital LLC purchased a new position in Tempus AI in the second quarter valued at $2,301,000. Federated Hermes Inc. acquired a new position in shares of Tempus AI during the second quarter worth about $19,886,000. Revolution Growth Management Company Inc. purchased a new stake in shares of Tempus AI in the 2nd quarter valued at approximately $128,133,000. Finally, Allen Operations LLC purchased a new position in Tempus AI in the second quarter valued at $3,831,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on TEM shares. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Bank of America lifted their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Wolfe Research assumed coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Loop Capital boosted their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Finally, Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the company from $45.00 to $65.00 in a report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $56.00.

Insider Buying and Selling at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares of the company’s stock, valued at approximately $358,780,403.82. The trade was a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Ryan Fukushima sold 120,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00. Following the completion of the transaction, the chief operating officer now directly owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. The trade was a 10.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 845,041 shares of company stock valued at $35,125,473.

Tempus AI Stock Down 0.5 %

Shares of TEM stock opened at $35.12 on Monday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock’s 50 day moving average is $50.06. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.